134 related articles for article (PubMed ID: 10445021)
21. The United States Food and Drug Administration and the end of antibiotics.
Shlaes DM; Moellering RC
Clin Infect Dis; 2002 Feb; 34(3):420-2. PubMed ID: 11774094
[No Abstract] [Full Text] [Related]
22. The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process.
Roden DM; Temple R
Circulation; 2005 Apr; 111(13):1697-702. PubMed ID: 15811869
[No Abstract] [Full Text] [Related]
23. The United States Food and Drug Administration and noninferiority margins in clinical trials of antimicrobial agents.
Powers JH; Ross DB; Brittain E; Albrecht R; Goldberger MJ
Clin Infect Dis; 2002 Mar; 34(6):879-81. PubMed ID: 11850875
[No Abstract] [Full Text] [Related]
24. [Apheresis treatment for rheumatoid arthritis].
Kempe K; Tsuda H
Nihon Rinsho; 2005 Jan; 63 Suppl 1():644-8. PubMed ID: 15799435
[No Abstract] [Full Text] [Related]
25. Cooling then culling blood complexes combats arthritis.
Page H
JAMA; 1982 Aug; 248(6):632. PubMed ID: 7047774
[No Abstract] [Full Text] [Related]
26. New use approved for Vioxx.
FDA Consum; 2002; 36(4):3. PubMed ID: 12184302
[No Abstract] [Full Text] [Related]
27. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
28. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis.
Yu X; Ma J; Tian J; Jiang S; Xu P; Han H; Wang L
J Clin Rheumatol; 2007 Aug; 13(4):193-8. PubMed ID: 17762452
[TBL] [Abstract][Full Text] [Related]
29. Errors in 'Trials and error'.
Miller DD
Nat Biotechnol; 2006 Jul; 24(7):747. PubMed ID: 16841048
[No Abstract] [Full Text] [Related]
30. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.
Peck CC; Rubin DB; Sheiner LB
Clin Pharmacol Ther; 2003 Jun; 73(6):481-90. PubMed ID: 12811358
[No Abstract] [Full Text] [Related]
31. Cryopheresis: immunochemical modulation and clinical response in autoimmune disease.
Smith JW; Kayashima K; Katsume C; Abe Y; Matsubara S; Shinagawa S; Ueno M; Wysenbeek A; Malchesky PS; Krakauer RS; Nosé Y
Trans Am Soc Artif Intern Organs; 1982; 28():391-5. PubMed ID: 7164269
[No Abstract] [Full Text] [Related]
32. Drug development research: the process.
Sataloff RT
Ear Nose Throat J; 2008 Aug; 87(8):420-2. PubMed ID: 18712686
[No Abstract] [Full Text] [Related]
33. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
34. Drive for drugs leads to baby clinical trials.
Nature; 2006 Mar; 440(7083):406-7. PubMed ID: 16554774
[No Abstract] [Full Text] [Related]
35. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
[No Abstract] [Full Text] [Related]
36. Trials and error.
Jacobs T
Nat Biotechnol; 2005 Dec; 23(12):1481. PubMed ID: 16333284
[No Abstract] [Full Text] [Related]
37. FDA tightens human oversight.
Dove A
Nat Med; 2001 Jun; 7(6):646. PubMed ID: 11385485
[No Abstract] [Full Text] [Related]
38. To market, to market. The nuts and bolts of prescription drug approval.
Peterson AM
Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443
[No Abstract] [Full Text] [Related]
39. Drug development: improving the process.
Peck CC
Food Drug Law J; 1997; 52(2):163-7. PubMed ID: 10557553
[No Abstract] [Full Text] [Related]
40. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
